CD9 and cancer: Antibodies targeting CD9 reduced cell surface trafficking of ADAMs and disrupted the interactions between CD9 and these ADAMs, impairing Notch activity and inhibiting the ability of cancer cells to migrate and grow (Lu et al., 2020).